Skip to content
MarketScale
‹ Back to IndustriesHealthcare

New Algorithm Uses CT Data to Create 3D Map and Better Assess Osteoarthritis

Engineers, radiologists and physicians based in the UK have developed a new technique for improving clinical imaging. It uses an algorithm to create a detailed three-dimensional map of a patient’s joint using computed tomography (CT) data. The team, led by co-author Tom Turmezei, Ph.D. of Cambridge University, recently reported on their breakthrough with a journal article titled…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Engineers, radiologists and physicians based in the UK have developed a new technique for improving clinical imaging. It uses an algorithm to create a detailed three-dimensional map of a patient’s joint using computed tomography (CT) data. The team, led by co-author Tom Turmezei, Ph.D. of Cambridge University, recently reported on their breakthrough with a journal article titled “A new quantitative 3D approach to imaging of structural joint disease,” which appeared in the June 2018 edition of Scientific Reports.

The team knew that the ability to assess OA with 2D radiographs was not good enough to detect subtle changes that could have important implications for patients, doctors, and researchers. To meet this challenge, they worked to develop a new algorithm for the structural assessment of joints including hips, knees and ankles in 3D. Their recent technical validation study showed the technique was successful.

The algorithm maps joint space width to the nearest tenth of a millimeter. Mapping joint space width in 3D from clinical CT data has the potential to enhance understanding of osteoarthritis and how patients progress to joint failure—leading to better and earlier interventions.

Early Detection Gives Osteoarthritis Patients More Options

The 3D mapping technique has the potential to be more than twice as sensitive as radiographs in detecting small changes in joint space widths. Using the algorithm, clinicians will be able to use CT scans to map a marker of osteoarthritis across a joint. Why does it matter? Because early detection leads to earlier treatment. Doctors could identify patients with disease earlier than the current gold standard, allowing important interventions to be started before the joint fails. Patients will have the opportunity to try lifestyle changes and physiotherapy instead of immediately facing surgery.

All clinical CT imaging was performed on a 64-slice Siemens Definition AS system.

“It will be an important next step to use JSM to investigate whether differences in positioning and load-bearing have any effect on joint space width in 3D,” the authors wrote. “A straightforward solution for prospective studies would be to perform knee and ankle CT in a standing position (as used in clinical practice), and to standardise supine hip positioning by strapping feet together.”

Evaluating New Therapies

In addition, the new 3D method will likely allow researchers to determine whether new therapies in development are effective in a realistic timescale for clinical trials. This is something that has not been possible using radiographs.

CurveBeam designs and manufactures Cone Beam CT imaging equipment for the orthopedic and podiatric specialties. Bilateral, weight bearing scans of the foot and ankle give physicians the information necessary to assess the biomechanical spatial relationships and alignment of the lower extremities.

To learn about a recent grant awarded to the University of Kansas to study joint space biomarkers via weight bearing CT, click here.

Read more at curvebeam.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

The FDA approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara for multiple inflammatory diseases, which means it may be substituted without consulting the prescriber, subject to state pharmacy laws. A Springer analysis reported 26 interchangeable biosimilars approved since 2020 and said average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024. The operational pressure shifts to formulary, payer, and specialty pharmacy workflow design.

  • 01Interchangeability is becoming the default ask, not an afterthought: Springer found 17 of 26 approvals pursued interchangeability concurrently, which changes how buyers should time contracting and conversions.
  • 02Springer reported average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024, which can compress planning windows for monitoring and implementation.
  • 03A new interchangeable ustekinumab option means the hard work is no longer clinical, it is operational: NDC mapping, EMR preference lists, substitution rules by state, and patient communications decide whether savings show up.

Sep 8, 2026

AAO-HNSF hearing loss guideline moves audiograms and amplification into primary care

AAO-HNSF’s new age-related hearing loss guideline calls for screening adults starting at age 50 and escalating to otoscopy, audiogram, and appropriately fit amplification. It shifts hearing loss from “patient complaint” to a routine primary-care workflow. The pressure shows up in audiology capacity, referral design, and documentation standards.

  • 01Screening at age 50 becomes a repeatable workflow, so capacity planning shifts from episodic ENT referrals to steady primary-care volume, especially where annual wellness visits are a dominant access point.
  • 02The guideline’s escalation sequence, screen, otoscopy, audiogram, amplification, then cochlear implant candidacy evaluation, creates a measurable funnel that health systems can instrument in the EHR and manage like any other pathway.
  • 03Asymmetric loss remains a separate trigger for MRI in many settings, and 2026 pre-proof work using NHANES and SEER highlights why imaging criteria choices can swing scan volume, a budgeting and radiology access issue, not a clinical footnote.

Sep 7, 2026

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

Accenture will keep supporting Australia’s My Health Record under a new three-year contract. ADHA is moving the platform to a multi-supplier operating model. The shift raises questions about shared integration discipline, tooling, and accountability when changes hit production.

  • 01Multi-supplier delivery is spreading across national-scale health platforms, as ADHA's My Health Record shift shows, moving risk from vendor selection to integration, runbooks, and accountability.
  • 02GenAI model upgrades are arriving with healthcare-specific claims, but the procurement work moves to evidence, safety controls, and monitoring once models sit inside clinical workflows.
  • 03Embedded AI expands the cyber asset inventory problem: if teams cannot discover the AI components across endpoints and devices, they cannot reliably secure or audit them.

Sep 7, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512